Analytic Time

3 - 10 days

MiChart Code
BCR/ABL1 Kinase Domain Mutation
Soft Order Code
KMBCR

Test Updated:

Synonyms

MLABEL
KMBCR
BCR Kinase Muation Analysis
ABLAMP
ABL-1 KINASE MUTATION ANALYSIS
ABLAMPS
ABL1 Kinase Domain Mut'n Shad
BCRABL Kinase Domain Mutation Detection
ABL1 Kinase Domain Mutation Detection
BCRABL Mutation Analysis
ABL Mutation Analysis
CML Mutation Analysis
CML Mutational Sequencing Assay

Looking to order a test?

We’ve provided helpful links to make ordering easy.

Find a Requisition

All specimens should be accompanied by a requisition.

Submitting Specimens

Learn about how to properly label and where to ship specimens.

Order Kits and Supplies

MLabs provides all the supplies necessary for the collection of specimens.

Test FAQ

Visit our provider FAQ and learn about common questions to ordering tests.

Test Overview

Test Methodology

Reverse transcription followed by nested Polymerase Chain Reaction (PCR).

Test Usage

Chronic myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome, the product of the t(9;22)(q34;q11) translocation. This translocation results in the BCR-ABL fusion protein with constitutive ABL tyrosine kinase activity. The kinase inhibitor imatinib (STI571, Gleevec) inhibits ABL kinase activity and is now the standard of care for early phase CML. Prolonged treatment with imatinib can lead to drug resistance, especially in patients with advanced disease. A large portion of resistant leukemias have acquired point mutations in the ABL kinase domain that renders the kinase resistant to the drug. This test detects greater than 85% of the reported ABL mutations (amino acid residues 235 through 368) that lead to imatinib resistance. The test may detect mutations prior to relapse.

Reference Range

Interpretive report provided. If a PCR product is detected, sequencing analysis will be performed to detect ABL1 kinase domain mutations if present.

* Reference ranges may change over time. Please refer to the original patient report when evaluating results.

Specimen Requirements

Collection Onsite

Collect blood or bone marrow in a lavender top tube. Refrigerate and send intact blood or bone marrow specimen within 48 hours of collection. Fresh tissue (preferably 0.5cm3, sent in RPMI) and fresh aspirates or body fluids are acceptable. Refrigerate and send, preferably within 24 hours. Frozen tissue specimens – preferably frozen with 1 hour of collection – may also be sent frozen on dry ice. Fresh cell suspensions in RPMI should be refrigerated and sent, preferably within 48 hours. Frozen cell suspensions – preferably frozen with 1 hour of collection – may also be sent frozen on dry ice.

Collection Offsite

Collect blood or bone marrow in a lavender top tube. Refrigerate and send intact blood or bone marrow specimen within 48 hours of collection. Fresh tissue (preferably 0.5cm3, sent in RPMI) and fresh aspirates or body fluids are acceptable. Refrigerate and send, preferably within 24 hours. Frozen tissue specimens – preferably frozen with 1 hour of collection – may also be sent frozen on dry ice. Fresh cell suspensions in RPMI should be refrigerated and sent, preferably within 48 hours. Frozen cell suspensions – preferably frozen with 1 hour of collection – may also be sent frozen on dry ice.

Normal Volume
5 mL EDTA (lavender) whole blood; 3 mL EDTA (lavender) bone marrow; Fresh/frozen tissue and fresh aspirates or body fluids; Fresh/frozen cells in RPMI. Extracted RNA is also acceptable if extracted in a CLIA certified laboratory.
Minimum Volume
 

Billing Information

CPT Code
81170
Pro Fee Code
 
LOINC
 

Have More Questions?

Explore our helpful billing resources:

Our High Standard

Quality that sets us apart

As the reference laboratory division of Michigan Medicine's Department of Pathology, MLabs shares the institution's commitment to applying established quality principles to clinical laboratory testing. Like other large organizations in complex, consequential fields, we rely on an established approach to monitor quality throughout the testing process.